Cedara Software, a subsidiary of Milwaukee-based Merge Healthcare, will unveil its Cedara PET/CT software application and its work-in progress Cedara I-Response, which visualizes tumor response to specific therapies.
Cedara PET/CT is available for integration into existing applications, such as a PACS, or as a standalone workstation. It has standard features for worklist management and offers configurable layouts, the company said. It also provides tools for reading from axial, sagittal, and coronal CT slices; manual or semiautomatic registration with cross correlation or triangulation between all images; standard visualization tools, standardized uptake value modes, and configurable color maps for PET, fused, and maximum intensity projection (MIP) displays.
The application borrows a paradigm from the reading of diagnostic CT datasets and offers the capability for displaying PET/CT images in a layout split across dual monitors in panoramic mode. For efficient study comparison, this review method allows simultaneous comparison of CT images; PET corrected, PET uncorrected, and PET/CT fused images; MIP; and other view sets, according to Mississauga, Ontario-based Cedara.
At RSNA 2006, the Cedara PET/CT workstation will be shown integrated into a PACS workstation environment using Cedara's work-in-progress C4 technology. The application is available now in the U.S., Canada, and the European Economic Area (EEA), the company said.
A part of the Cedara OncologyWorks family of products, Cedara I-Response has been designed for fast and efficient analysis of tumor response, Cedara said. The application is based on functional diffusion mapping (fDM) work conducted at the University of Michigan. The use of fDM technology allows the tool to monitor the early impact of anticancer drugs and radiation therapy by visualizing functional activity among multiple time points with individual, configurable layouts.
The product supports multiple modalities, provides automatic registration of datasets across multiple time points and modalities, and manages annotation layers and user roles, the firm said. In addition, automatic segmentation and contouring tools are available, and the software provides response evaluation criteria in solid tumors (RECIST), World Health Organization (WHO) criteria, and volume measurements, as well as quantitative calculations.
I-Response has received U.S. Food and Drug Administration 510(k) approval and is scheduled to be available next year.
By Jonathan S. Batchelor
AuntMinnie.com staff writer
November 15, 2006
Copyright © 2006 AuntMinnie.com
